Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D L van der Velden

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Critical Reviews in Oncology/Hematology|May 22, 2022
Prognostic value of CT characteristics in GEP-NET: A systematic reviewD L van der Velden, F C R Staal, E A Aalbersberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Molecular Tumor Boards: current practice and future needsD L van der Velden, C M L van Herpen, H W M van Laarhoven, et al.
European Journal of Cancer (Oxford, England : 1990)|June 18, 2022
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancerJ M van Berge Henegouwen, M Jebbink, L R Hoes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2019
Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patientsS B van Waalwijk van Doorn-Khosrovani, A Pisters-van Roy, L van Saase, et al.
Nature|October 2, 2019
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugsD L van der Velden, L R Hoes, H van der Wijngaart, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Critical Reviews in Oncology/Hematology|May 22, 2022
Prognostic value of CT characteristics in GEP-NET: A systematic reviewD L van der Velden, F C R Staal, E A Aalbersberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Molecular Tumor Boards: current practice and future needsD L van der Velden, C M L van Herpen, H W M van Laarhoven, et al.
European Journal of Cancer (Oxford, England : 1990)|June 18, 2022
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancerJ M van Berge Henegouwen, M Jebbink, L R Hoes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2019
Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patientsS B van Waalwijk van Doorn-Khosrovani, A Pisters-van Roy, L van Saase, et al.
Nature|October 2, 2019
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugsD L van der Velden, L R Hoes, H van der Wijngaart, et al.
Pageof 1